Faculty Presentations

Thursday, Nov. 17

Education Day – CNS Cancer Survivorship
Maintaining Neuro Health During Survivorship
8:00 – 10:45 a.m. | Ballroom B
MODERATOR: Milan G. Chheda, MD

Managing Distress During Survivorship
10:45 a.m. – 1:00 p.m. | Ballroom B
MODERATOR: Milan G. Chheda, MD


Education Day – Cancer Neuroscience: Glioma Neuroscience: Influence of Gliomas on Neurons
Neuronal Regulation of Gliomagenesis
10:35 – 10:55 a.m. | East Hall
SPEAKER: David H. Gutmann, MD PhD


Education Day – Cancer Neuroscience: Neuroscience of Brain Metastases
11:30 a.m. – 1:00 p.m. | East Hall
MODERATOR: David H. Gutmann, MD PhD


Education Day – CNS Cancer Survivorship: Building Community During Survivorship
Financial Toxicity in Cancer: Incorporating Cost Discussions into Routine Care
2:15 – 2:30 p.m. | Ballroom B
SPEAKER: Mary C. Politi, PhD
*This session will have CME.

Panel Discussion
3:00 – 3:35 p.m. | Ballroom B
PANELIST: Mary C. Politi, PhD

Friday, Nov. 18

Concurrent Session: Evaluating MEK Inhibition for Treatment of NF1-Relelated Nervous System Tumors
MEKi—A Potential Partner in Treatment of MPNST
7:50 – 8:05 a.m. | Ballroom A
PRESENTER: Angela Hirbe, MD PhD

Panel Discussion
8:20 – 8:45 a.m. | Ballroom A
PANELIST: Angela Hirbe, MD PhD


Plenary I
Keynote Presentation: Spatial-Proteomics Analysis of Cancer Immunotherapy
9:10 – 9:40 a.m. | East Hall
KEYNOTE SPEAKER: Robert D. Schreiber, PhD (he/him/his) – Washington University School of Medicine in St Louis
*This session will have CME.


Concurrent Session: Challenges with Surgical Window of Opportunity and Phase 0 Trials in Neuro-Oncology
Phase 0 Clinical Trials for Novel Glioma Nanotechnologies
11:05 – 11:25 a.m. | East Hall
SPEAKER: Alexander H. Stegh, PhD
*This session will have CME.

12:05 – 12:15 p.m. | East Hall
PANELIST: Alexander H. Stegh, PhD
*This session will have CME.


Abstract Session: Neuroimaging I
NIMG-43 – Diffusion basis spectrum imaging distinguishes high-grade glioma treatment effect from tumor progression
2:00 – 2:05 p.m. | Ballroom B
PRESENTER: Rowland H. Han, MD


Abstract Session: Basic Science II
TMIC-05 – Single-cell multi-omic analysis of sporadic vestibular schwannomas reveals Schwann cells with an injury phenotype and an association between tumor size and macrophage infiltrate
5:35 – 5:40 p.m. | Ballroom A
PRESENTER: Bhuvic Patel, MD


7:30 – 9:30 p.m. | West/Central Hall

CSIG-19 – The PI3K/Akt/mTOR signaling cascade may contribute to sex differences in glioblastoma
PRESENTER: Jasmin Sponagel, PhD

EPCO-22 – Single cell analysis to understand sex differences in GBM outcome
PRESENTER: Lorida Llaci, BS

EPCO-29 – KLF5 is required for the sex-differences across multiple tumorigenic phenotypes in pediatric glioblastoma (GBM)
PRESENTER: Tamara Abou-Antoun, PhD

EXTH-22 – Targeting a newly discovered immune checkpoint, Siglec-15, increases oncolytic efficacy of Zika virus (ZIKV) in glioblastoma (GBM)
PRESENTER: Ashwani Kesarwani, PhD

IMMU-30 – The role of CD4 T cells in antitumor immunity against brain tumors
PRESENTER: Andrew T. Coxon, BS

IMMU-35 – TREM2 restrains anti-tumor cell activity of myeloid cells in glioblastoma

MODL-19 – Creation of an in vitro model system for the study of H3.1K27M DMG
PRESENTER: Joseph S. Lagas, B.S.

TMET-13 – Sex differences in glucose metabolism and mitochondrial function in glioblastoma implicate hypoxia-inducible factor 1 alpha (HIF1A) activity
PRESENTER: Joseph E. Ippolito, MD PhD

TMET-23 – Glioblastoma exhibit sex differences in branched-chain amino acid metabolism
PRESENTER: Jasmin Sponagel, PhD

NIMG-109 – A pilot study of lymphoscintigraphy with tracer injection in the human brain
PRESENTER: Andrew T. Coxon, BS

Saturday, Nov. 19

Abstract Session: Basic Science III
MODL-25 – Analysis of tumor cell heterogeneity in a human neural progenitor-based model of glioblastoma reveals neurodevelopmental programs and cytoskeletal dynamics
1:55 – 2:00 p.m | Ballroom B
PRESENTER: Patrick A. DeSouza


Concurrent Session: Mechanisms of Tumor Immortality
The Clinical Significance and Genetic Regulation of TERT
4:40 – 5:05 p.m. | East Hall
SPEAKER: Albert H. Kim, MD, PhD

5:30 – 5:45 p.m. | East Hall
PANELIST: Albert H. Kim, MD, PhD

Sunday, Nov. 20

Concurrent Session: Translating Genomic Findings into Preclinical Models to Generate Hypothesis and Marker-Based Clinical Trials in Rare CNS Cancers
Modeling Low-Grade Tumors in Cancer Predisposition Syndromes
9:40 AM – 10:00 a.m. | Ballroom C
PRESENTER: David H. Gutmann, MD PhD

10:20 AM – 10:30 a.m. | Ballroom C
PANELIST: David H. Gutmann, MD PhD